Press Releases

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

November, 07 2023

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced it will host a virtual R&D Day event on Thursday, November 9, 2023 at 1:30 p.m. ET. To register, click here. The event will feature a presentation from Dr. Amit Pandya, former President of the…

Read More

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

November, 01 2023

Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025 BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the closing of its previously announced private placement financing (the “PIPE”). In the PIPE, VYNE received aggregate gross proceeds of $88.2 million, before deducting placement agent fees and offering expenses, from the sale of 10,652,543 shares of common stock at a purchase price of $2.245 per share and, in lieu of…

Read More

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

October, 30 2023

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritis Following completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 2024, followed by Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024 Preclinical data and clinical programs to be discussed at R&D Day event on November 9, 2023 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company…

Read More

VYNE Therapeutics Announces Private Placement of $88 Million

October, 30 2023

Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of $88 million, before deducting placement agent fees and offering expenses. The PIPE was led by Access…

Read More

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

October, 30 2023

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b clinical trial in the first half of 2024 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a…

Read More

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September, 06 2023

BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will also be available for 1-on-1 meetings with investors. Presentation Details Company Presentation: Monday, September 11, 2023 at 7:00 AM ET Speaker: David Domzalski, President and Chief Executive Officer Registration: Webcast Link The replay of the webcast will…

Read More